

世界权威医学著作英文原版



# WINTROBE

# 临床血液病学

## WINTROBE'S

## CLINICAL HEMATOLOGY

## 11TH EDITION

(第11版)

第2卷

JOHN P. GREER

JOHN FOERSTER

JOHN N. LUKENS

GEORGE M. RODGERS

FRIXOS PARASKEVAS

BERTIL GLADER

山东科学技术出版社 [www.lkj.com.cn](http://www.lkj.com.cn)



LIPPINCOTT WILLIAMS & WILKINS

世界权威医学著作英文原版



# WINTROBE

## 临床血液病学

WINTROBE'S  
CLINICAL HEMATOLOGY  
11TH EDITION

(第11版)

第2卷

JOHN P. GREER

JOHN FOERSTER

JOHN N. LUKENS

GEORGE M. RODGERS

FRIXOS PARASKEVAS

BERTIL GLADER

山东科学技术出版社



LIPPINCOTT WILLIAMS & WILKINS

# WINTROBE'S CLINICAL HEMATOLOGY

---

*ELEVENTH EDITION*

---

## VOLUME 2

*EDITED BY*

**John P. Greer, MD**

PROFESSOR OF MEDICINE AND PEDIATRICS  
DEPARTMENTS OF MEDICINE AND PEDIATRICS  
DIVISION OF HEMATOLOGY/ONCOLOGY  
VANDERBILT UNIVERSITY SCHOOL OF MEDICINE  
NASHVILLE, TENNESSEE

**John Foerster, MD, FRCPC**

PROFESSOR OF MEDICINE  
DIVISION OF HEMATOLOGY/ONCOLOGY  
UNIVERSITY OF MANITOBA FACULTY OF MEDICINE  
DIRECTOR OF RESEARCH  
ST. BONIFACE GENERAL HOSPITAL  
WINNIPEG, MANITOBA  
CANADA

**John N. Lukens, MD**

PROFESSOR OF PEDIATRICS, EMERITUS  
DIVISION OF PEDIATRIC HEMATOLOGY/ONCOLOGY  
VANDERBILT UNIVERSITY SCHOOL OF MEDICINE  
NASHVILLE, TENNESSEE

**George M. Rodgers, MD, PhD**

PROFESSOR OF MEDICINE AND PATHOLOGY  
UNIVERSITY OF UTAH SCHOOL OF MEDICINE  
HEALTH SCIENCES CENTER  
VETERANS AFFAIRS MEDICAL CENTER  
MEDICAL DIRECTOR, COAGULATION LABORATORY  
ARUP LABORATORIES  
SALT LAKE CITY, UTAH

**Frixos Paraskevas, MD**

ASSOCIATE  
INSTITUTE OF CELL BIOLOGY  
UNIVERSITY OF MANITOBA FACULTY OF MEDICINE  
CANCER CARE MANITOBA  
WINNIPEG, MANITOBA  
CANADA

**Bertil Glader, MD, PhD**

PROFESSOR OF PEDIATRICS  
DIVISION OF HEMATOLOGY/ONCOLOGY  
STANFORD UNIVERSITY SCHOOL OF MEDICINE  
STANFORD, CALIFORNIA

*WITH CONTRIBUTING AUTHORS*



**LIPPINCOTT WILLIAMS & WILKINS**

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

**图书在版编目 (CIP) 数据**

WINTROBE 临床血液病学 / (美) 格里尔 (Greer, J. P.) 等编  
影印本. — 济南: 山东科学技术出版社, 2004. 5  
ISBN 7-5331-3708-6

I. W... II. 格... III. 血液病—诊疗—英文 IV. R55

中国版本图书馆 CIP 数据核字 (2004) 第 027508 号

*Wintrobe's Clinical Hematology*, 11/e by John P. Greer, M. D.,  
et. al; First published by Lippincott Williams & Wilkins, Inc.  
Lippincott Williams & Wilkins, Inc. has authorized this Reprint.  
This Reprint is authorized for sale in the People's Republic of China  
only.  
Chinese reprint copyright © 2004 by  
Shandong Science & Technology Press  
ALL RIGHTS RESERVED

图字: 15-2004-024

**WINTROBE 临床血液病学**

(第 11 版)

JOHN P. GREER

JOHN FOERSTER

JOHN N. LUKENS

GEORGE M. RODGERS

FRIXOS PARASKEVAS

BERTIL GLADER

(影印本)

---

**出版者: 山东科学技术出版社**

地址: 济南市玉函路 16 号

邮编: 250002 电话: (0531) 2065109

网址: [www.lkj.com.cn](http://www.lkj.com.cn)

电子邮件: [sdkj@jn-public.sd.cninfo.net](mailto:sdkj@jn-public.sd.cninfo.net)

**发行者: 山东科学技术出版社**

地址: 济南市玉函路 16 号

邮编: 250002 电话: (0531) 2020432

**印刷者: 莱芜市圣龙印务书刊有限责任公司**

地址: 莱芜市凤城西大街 149 号

邮编: 271100 电话: (0634) 6113596

---

开本: 889mm×1194mm 1/16

印张: 176.5

字数: 6500 千

版次: 2004 年 5 月第 1 版第 1 次印刷

---

ISBN 7-5331-3708-6

R · 1104

定价 (共 2 卷): 480.00 元

© 2004 by LIPPINCOTT WILLIAMS & WILKINS  
530 Walnut Street  
Philadelphia, PA 19106 USA  
LWW.com

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright.

Printed in the USA  
First Edition, 1942  
Second Edition, 1946  
Third Edition, 1951  
Fourth Edition, 1956  
Fifth Edition, 1961  
Sixth Edition, 1967  
Seventh Edition, 1974  
Eighth Edition, 1981  
Ninth Edition, 1993  
Tenth Edition, 1999

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of health care providers to ascertain the FDA status of each drug or device planned for use in their clinical practice.

10987654321

*To Dr. Maxwell M. Wintrobe*



# Contents

---

Contributing Authors xi  
Preface xvii  
Color Plates follow p. xviii

## VOLUME 1

### PART I

#### **Laboratory Hematology**

---

1. Examination of the Blood and Bone Marrow 3  
*Sherrie L. Perkins*
2. Clusters of Differentiation 27  
*Frixos Paraskevas*
3. Clinical Flow Cytometry 99  
*Frixos Paraskevas*
4. Cytogenetics 131  
*Sheila N. J. Sait and Maria R. Baer*
5. Molecular Biology and Hematology 153  
*Rebecca L. Shattuck-Brandt and Stephen J. Brandt*

### PART II

#### **Normal Hematologic System**

---

##### **Section 1. Hematopoiesis**

6. Origin and Development of Blood Cells 169  
*Maurice C. Bondurant and Mark J. Koury*

##### **Section 2. The Erythrocyte**

7. Erythropoiesis 195  
*Emmanuel N. Dessypris and Stephen T. Sawyer*
8. The Mature Erythrocyte 217  
*Marilyn J. Telen and Russel E. Kaufman*
9. Destruction of Erythrocytes 249  
*Bertil Glader*

##### **Section 3. Granulocytes and Monocytes**

10. Neutrophilic Leukocytes 267  
*Keith M. Skubitz*
11. The Human Eosinophil 311  
*Paige Lacy, Allan B. Becker, and Redwan Moqbel*
12. Basophilic Leukocytes: Mast Cells and Basophils 335  
*A. Dean Befus and Judah A. Denburg*
13. Mononuclear Phagocytes 349  
*J. Brice Weinberg*
14. Phagocytosis 387  
*Frixos Paraskevas*

##### **Section 4. Lymphocytes**

15. Lymphocytes and Lymphatic Organs 409  
*Frixos Paraskevas*
16. B Lymphocytes 439  
*Frixos Paraskevas*
17. T Lymphocytes and Natural Killer Cells 475  
*Frixos Paraskevas*
18. Effector Mechanisms in Immunity 527  
*Frixos Paraskevas*

##### **Section 5. Hemostasis**

19. Megakaryocytes and Platelets 605  
*Kenneth Kaushansky and Gerald J. Roth*
20. Platelet Function in Hemostasis and Thrombosis 651  
*David C. Calverley and Lori J. Maness*
21. Blood Coagulation and Fibrinolysis 677  
*Kathleen Brummel-Ziedins, Thomas Orfeo, Nancy Swords Jenny, Stephen J. Everse, and Kenneth G. Mann*
22. Endothelium: Angiogenesis and the Regulation of Hemostasis 775  
*Paul J. Shami and George M. Rodgers*

### PART III

#### **Therapeutic Modalities**

---

23. Red Cell, Platelet, and White Cell Antigens 791  
*Kathryn E. Weibert, Howard H. W. Chan, James William Smith, Nancy M. Heddle, and John G. Kelton*
24. Transfusion Medicine 831  
*Susan A. Galel, James M. Malone III, and Maureen K. Viele*
25. Hematopoietic Stem Cell Transplantation 883  
*Richard A. Nash*
26. Gene Therapy for Hematologic Disorders, Human Immunodeficiency Virus Infection, and Cancer 911  
*John F. Tisdale, Cynthia E. Dunbar, Jay N. Lozier, and Stacey A. Goodman*

### PART IV

#### **Disorders of Red Cells**

---

##### **Section 1. Introduction**

27. Anemia: General Considerations 947  
*Bertil Glader*

##### **Section 2. Disorders of Iron Metabolism and Heme Synthesis**

28. Iron Deficiency and Related Disorders 979  
*Nancy C. Andrews*

## 29. Sideroblastic Anemias 1011

*Sylvia S. Bottomley*

## 30. Hemochromatosis 1035

*Corwin Q. Edwards*

## 31. Porphyria 1057

*Sylvia S. Bottomley***Section 3. Hemolytic Anemia**

## 32. Hereditary Spherocytosis and Other Anemias Due to Abnormalities of the Red Cell Membrane 1089

*William C. Mentzer and Bertil Glader*

## 33. Hereditary Hemolytic Anemias Due to Enzyme Disorders 1115

*Bertil Glader*

## 34. Mechanisms of Immune Destruction of Erythrocytes 1141

*Charles J. Parker*

## 35. Autoimmune Hemolytic Anemias 1157

*Anne T. Neff*

## 36. Alloimmune Hemolytic Disease of the Fetus and Newborn 1183

*Anne F. Eder and Catherine S. Manno*

## 37. Paroxysmal Nocturnal Hemoglobinuria 1203

*Charles J. Parker and Russell E. Ware*

## 38. Acquired Nonimmune Hemolytic Disorders 1223

*Michael R. Jeng and Bertil Glader***Section 4. Hereditary Disorders of Hemoglobin Structure and Synthesis**

## 39. Abnormal Hemoglobins: General Principles 1247

*John N. Lukens*

## 40. Sickle Cell Anemia and Other Sickling Syndromes 1263

*Winfred C. Wang*

## 41. Unstable Hemoglobin Disease 1313

*John N. Lukens*

## 42. Thalassemias and Related Disorders: Quantitative Disorders of Hemoglobin Synthesis 1319

*Caterina Borgna-Pignatti and Renzo Galanello***Section 5. Other Red Cell Disorders**

## 43. Megaloblastic Anemias: Disorders of Impaired DNA Synthesis 1367

*Ralph Carmel*

## 44. Acquired and Inherited Aplastic Anemia Syndromes 1397

*Eva C. Guinan and Akiko Shimamura*

## 45. Red Cell Aplasia 1421

*Emmanuel N. Dessypris and Jeffrey M. Lipton*

## 46. Congenital Dyserythropoietic Anemias 1439

*Peter W. Marks and Bertil Glader*

## 47. Anemias Secondary to Chronic Disease and Systemic Disorders 1445

*Robert T. Means, Jr.*

## 48. Anemias Unique to Pregnancy and the Perinatal Period 1467

*Robert D. Christensen and Robin K. Ohls*

## 49. Hemoglobins Associated with Cyanosis: Methemoglobinemia and Low-Affinity Hemoglobins 1487

*John N. Lukens*

## 50. Erythrocytosis 1495

*Robert T. Means, Jr.***VOLUME 2****PART V****Disorders of Hemostasis and Coagulation****Section 1. Introduction**

## 51. Diagnostic Approach to the Bleeding Disorders 1511

*George M. Rodgers***Section 2. Thrombocytopenia**

## 52. Thrombocytopenia: Pathophysiology and Classification 1529

*Shirley Parker Levine*

## 53. Thrombocytopenia Caused by Immunologic Platelet Destruction 1533

*Shirley Parker Levine*

## 54. Thrombotic Thrombocytopenic Purpura and Other Forms of Nonimmunologic Platelet Destruction 1555

*Shirley Parker Levine*

## 55. Miscellaneous Causes of Thrombocytopenia 1565

*Shirley Parker Levine***Section 3. Other Disorders of Primary Hemostasis**

## 56. Bleeding Disorders Caused by Vascular Abnormalities 1573

*Matthew M. Rees and George M. Rodgers*

## 57. Thrombocytosis 1591

*Shirley Parker Levine*

## 58. Qualitative Disorders of Platelet Function 1603

*Shirley Parker Levine***Section 4. Coagulation Disorders**

## 59. Inherited Coagulation Disorders 1619

*Kenneth D. Friedman and George M. Rodgers*

## 60. Acquired Coagulation Disorders 1669

*George M. Rodgers***Section 5. Thrombosis**

## 61. Thrombosis and Antithrombotic Therapy 1713

*Steven R. Deitcher and George M. Rodgers***PART VI****Nonmalignant Disorders of Leukocytes, the Spleen, and/or Immunoglobins**

## 62. Diagnostic Approach to Malignant and Nonmalignant Disorders of the Phagocytic and Immune Systems 1761

*Thomas L. McCurley and John P. Greer*

## 63. Neutropenia 1777

*Raymond G. Watts*

## 64. Qualitative Disorders of Leukocytes 1801

*Keith M. Skubitz*



65. Abnormalities of the Monocyte-Macrophage System: Lysosomal Storage Diseases 1819  
*Margaret M. McGovern and Robert J. Desnick*
66. Langerhans Cell Histiocytosis 1827  
*H. Stacy Nicholson*
67. Infectious Mononucleosis and Other Epstein-Barr Virus-Related Disorders 1837  
*Thomas G. Gross*
68. Primary Immunodeficiency Syndromes 1863  
*Anthony R. Hayward*
69. Acquired Immunodeficiency Syndrome 1875  
*Elaine M. Sloan and Jerome E. Groopman*
70. Disorders of the Spleen 1893  
*Jeremy Goodman, Martin I. Newman, and William C. Chapman*

## PART VII

**Hematologic Malignancies****Section 1. General Aspects**

71. Hematopoietic-Lymphoid Neoplasms: Principles of Diagnosis 1913  
*John B. Cousar*
72. Complications of Hematopoietic Neoplasms 1919  
*Madan H. Jagasia and Edward R. Arrowsmith*
73. Principles and Pharmacology of Chemotherapy 1945  
*Kenneth R. Hande*
74. Immunotherapy 1971  
*Stanford J. Stewart*
75. Supportive Care in Hematologic Malignancies 1997  
*Madhuri Vusirikala*

**Section 2. Acute Leukemias**

76. Molecular Genetics of Acute Leukemia 2045  
*Mary Ann Thompson*
77. Classification and Differentiation of the Acute Leukemias 2063  
*David R. Head*
78. Acute Lymphoblastic Leukemia in Adults 2077  
*Thai M. Cao and Steven E. Coutre*
79. Acute Myeloid Leukemia in Adults 2097  
*John P. Greer, Maria R. Baer, and Marsha C. Kinney*
80. Acute Lymphoblastic Leukemia in Children 2143  
*James A. Whitlock and Paul S. Gaynon*
81. Acute Myelogenous Leukemia in Children 2169  
*Robert J. Arceci and Richard Aplenc*
82. Acute Promyelocytic Leukemia 2191  
*Steven L. Soignet and Peter G. Maslak*
83. Myelodysplastic Syndromes 2207  
*Alan F. List, Avery A. Sandberg, and Donald C. Doll*

**Section 3. Myeloproliferative Disorders**

84. Chronic Myeloid Leukemia 2235  
*Ian Rabinowitz and Richard S. Larson*
85. Polycythemia Vera 2259  
*Robert T. Means, Jr.*

86. Myelofibrosis 2273  
*Douglas A. Clark and Wilbur L. Williams*
87. Systemic Mastocytosis 2285  
*Alexandra S. Worobec and Dean D. Metcalfe*

**Section 4. Lymphoproliferative Disorders**

88. Diagnosis and Classification of Non-Hodgkin Lymphomas 2301  
*Thomas L. McCurley and William R. Macon*
89. Molecular Aspects of Non-Hodgkin Lymphomagenesis 2325  
*Andreas Rosenwald, Louis M. Staudt, Justus Georg Duyster, and Stephan W. Morris*
90. Non-Hodgkin Lymphomas in Adults 2363  
*John P. Greer*
91. Non-Hodgkin Lymphomas in Children 2411  
*John T. Sandlund and Frederick G. Behm*
92. Chronic Lymphocytic Leukemia 2429  
*James B. Johnston*
93. Hairy Cell Leukemia 2465  
*James B. Johnston*
94. Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome 2485  
*John A. Zic, Monika G. Kiripolsky, Katherine S. Hamilton, and John P. Greer*
95. Hodgkin Disease 2521  
*Richard S. Stein and David S. Morgan*

**Section 5. Plasma Cell Dyscrasias**

96. Practical Aspects of the Clinical Approach to Patients with Monoclonal Immunoglobulin Disorders 2555  
*Philip R. Greipp and Rafael Fonseca*
97. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma 2565  
*Robert A. Kyle, S. Vincent Rajkumar, and John A. Lust*
98. Multiple Myeloma 2583  
*Angela Dispenzieri, Martha Q. Lacy, and Philip R. Greipp*
99. Immunoglobulin Light-Chain Amyloidosis (Primary Amyloidosis) 2637  
*Morie A. Gertz, Martha Q. Lacy, and Angela Dispenzieri*
100. Waldenström Macroglobulinemia 2667  
*Rafael Fonseca and Thomas E. Witzig*
101. Cryoglobulinemia, Heavy Chain Diseases, and Monoclonal Gammopathy-Associated Disorders 2683  
*Angela Dispenzieri and Morie A. Gertz*

**Appendixes**

- Appendix A. Normal Blood and Bone Marrow Values in Humans 2697  
*Sherrie L. Perkins*
- Appendix B. Comparative Hematology 2707  
*Harvey A. Ragan*

**PART V**

**Disorders of Hemostasis and Coagulation**

---



### CHAPTER 51

## Diagnostic Approach to the Bleeding Disorders

George M. Rodgers

---

- Clinical Evaluation of the Bleeding Patient
- Manifestations of Disordered Hemostasis
  - Bleeding into Skin and Soft Tissues
  - Hemarthrosis
  - Traumatic Bleeding
  - Miscellaneous Bleeding Manifestations
- Clinical Features of Inherited Bleeding Disorders
  - Age at Onset: Bleeding in the Neonate
  - Family History
- Clinical Features of Acquired Bleeding Disorders
  - Drug History
- Laboratory Methods for Study of Hemostasis and Blood Coagulation
  - Tests of Vascular and Platelet Phases
    - Bleeding Time
    - Platelet Enumeration
    - Platelet Volume Measurements
    - Platelet Function Assays
  - Tests of Coagulation Phase
    - Partial Thromboplastin Time
    - Prothrombin Time
    - Thromboplastin Generation Test
    - Assay of Plasma Fibrinogen

- Thrombin Time and Related Techniques
- Tests for Fibrin-(Fibrinogen)-Degradation Products and D-Dimer
- Tests for Factor XIII Activity
- Tests for Fibrinolysis
- Bioassays for Coagulation Factors
- Tests for Inhibitors of Coagulation
- Tests for Physiologic Inhibitors of Coagulation
- Automated Coagulation Methods
- Chromogenic and Fluorometric Techniques
- Initial Laboratory Evaluation
  - Primary Screening Tests
  - Confirmatory Tests
    - Thrombocytopenia
    - von Willebrand Disease
    - Qualitative Platelet Disorders
    - Disorders of the Intrinsic Pathway of Coagulation
    - Disorders of the Common Pathway of Coagulation
    - Disorders of the Extrinsic Pathway of Coagulation
    - Disorders in Which Results of Primary Screening Tests Are Normal
- Preoperative Hemostasis Evaluation
- Evaluation of the Neonate

---

Except for that which occurs during menstruation, spontaneous bleeding is abnormal. Surprisingly, little blood is lost, even after large injuries, because of the efficiency with which vascular integrity is normally maintained and the rapidity with which it is restored after injury. In general, these phenomena reflect the

functional effectiveness of normal hemostasis (see Chapters 19 to 22). It must be recognized, however, that the adequacy of hemostasis is only relative, and despite the presence of normal vessels, platelets, and coagulation factors, bleeding can occur as the result of localized pathologic processes.

TABLE 51.1. Clinical Distinction between Disorders of Vessels and Platelets and Disorders of Blood Coagulation

Finding	Disorders of Coagulation	Disorders of Platelets or Vessels
Petechiae	Rare	Characteristic
Deep dissecting hematomas	Characteristic	Rare
Superficial ecchymoses	Common; usually large and solitary	Characteristic; usually small and multiple
Hemarthrosis	Characteristic	Rare
Delayed bleeding	Common	Rare
Bleeding from superficial cuts and scratches	Minimal	Persistent; often profuse
Sex of patient	80–90% of inherited forms occur only in male patients	Relatively more common in females
Positive family history	Common	Rare (except von Willebrand disease and hereditary hemorrhagic telangiectasia)

The 11 chapters in Part V deal with disorders that result from abnormalities of the hemostatic process. Chapter 51 is a summary of the diagnostic approach to these disorders and includes a brief discussion of laboratory methods for their study. In subsequent chapters, individual disorders are considered in six categories: thrombocytopenia (Chapters 52 to 55), bleeding disorders caused by vascular abnormalities (Chapter 56), thrombocytosis (Chapter 57), disorders of platelet function (Chapter 58), inherited coagulation disorders (Chapter 59), and acquired coagulation disorders (Chapter 60). The pathophysiology of thrombosis and the principles of antithrombotic therapy are summarized in Chapter 61.

## CLINICAL EVALUATION OF THE BLEEDING PATIENT

A careful evaluation of the patient presenting with a bleeding disorder can often provide valuable clues as to whether the abnormality resides in the vessels, platelets, or the process of blood coagulation; a carefully obtained history can usually establish whether the disorder is inherited or acquired; and the physical examination may reveal findings such as the characteristic skin lesions of hereditary hemorrhagic telangiectasia, which alone may provide the diagnosis of a previously perplexing bleeding problem. Results of the clinical evaluation should lead to a rational and efficient laboratory investigation. If laboratory studies are to be used to maximal advantage in terms of time and expense, they should supplement and not supersede a careful review of the history and the physical examination.

It is important to ask specific questions about bleeding because people with normal hemostasis may believe they bleed excessively (1). Certain questions may discriminate between those with normal and abnormal hemostasis, including whether excessive bleeding occurs after tooth extraction or small cuts, whether spontaneous bruising or muscle bleeding occurs, or whether the patient has ever been transfused or treated with blood products (1).

## MANIFESTATIONS OF DISORDERED HEMOSTASIS

Certain signs and symptoms are virtually diagnostic of disordered hemostasis. They can be divided arbitrarily into two groups: those seen more often in disorders of blood coagulation and those most commonly noted in disorders of the vessels and platelets. The latter group is often called *purpuric disorders* because cutaneous and mucosal bleeding usually are prominent. The clinical findings that are most valuable in distinguishing between these two broad categories are summarized in Table 51.1. Although these criteria are relative, they provide

valuable clues to the probable diagnosis if they are applied to the predominant clinical features in a given patient.

## Bleeding into Skin and Soft Tissues

Petechiae are characteristic of an abnormality of the vessels or the platelets, such as thrombocytopenia, and are exceedingly rare in the coagulation disorders. These lesions are small capillary hemorrhages ranging from the size of a pinhead to much larger (Fig. 51.1). They characteristically develop and regress in crops and are most conspicuous in areas of increased venous pressure, such as the dependent parts of the body and areas subjected to pressure or constriction from girdles or stockings. In patients with scurvy, petechiae may be distributed around hair follicles in the "saddle area" of the thighs and buttocks (see Fig. 56.6). Petechiae must be distinguished from small telangiectasias and angiomas. Vascular structures such as telangiectasias or angiomas blanch with pressure, whereas petechiae do not.



Figure 51.1. Diffuse petechial rash induced by a tourniquet in a patient with chronic idiopathic thrombocytopenic purpura (platelet count =  $40 \times 10^9/L$ ).



**Figure 51.2.** Large dissecting hematoma of thigh in a patient with hemophilia A. The lesion resulted from a slight bump to the inguinal area and spread to involve the entire thigh. See Color Plate. (Courtesy of Dr. John Lukens.)

In the purpuric disorders, petechiae commonly are associated with multiple superficial ecchymoses, which usually develop without perceptible trauma but seldom spread into deeper tissues. Small isolated ecchymoses are commonly noted in apparently normal women, especially on the legs, and in small children.

Although large superficial ecchymoses may be seen in association with the coagulation disorders, the most characteristic

lesion is the large spreading hematoma (Fig. 51.2). Such hematomas may arise spontaneously or after trivial trauma and often spread to involve an entire limb by dissecting within muscles and deep fascial spaces, often with minimal discoloration of the overlying skin.

### Hemarthrosis

Hemorrhage into synovial joints is virtually diagnostic of a severe inherited coagulation disorder, most commonly hemophilia A or hemophilia B, and is rare in disorders of the vessels and platelets or in acquired coagulation disorders. This disabling problem often develops with pain and swelling as chief symptoms but without discoloration or other external evidence of bleeding (Fig. 51.3). Subperiosteal hemorrhages in children with scurvy and swollen painful joints that may develop in some patients with allergic purpura occasionally may be confused with hemarthrosis.

### Traumatic Bleeding

The unavoidable traumas of daily life and even minor surgical procedures are a greater challenge to hemostasis than any test yet developed in the laboratory. In contrast to "spontaneous" bleeding manifestations, bleeding after trauma in a person with a hemorrhagic diathesis differs in a quantitative way from that which would normally be expected in terms of the amount, duration, and magnitude of the inciting trauma. Such variables are extremely difficult to assess accurately by taking the patient's history. The amount of blood lost may be exaggerated by the patient. The need for transfusions and the number administered may serve as a rough guide. The patient's statement concerning the duration of bleeding is more reliable. Detailed inquiry as to past injuries and operations must be made because the patient is likely to forget procedures or injuries that were uncomplicated and to dwell on those in which bleeding was a problem. Whether reoperation was required for prolonged bleeding after tooth extraction or other minor surgical procedures may be helpful in identifying a patient with abnormal hemostasis.

In individuals with a coagulation disorder, the onset of bleeding after trauma often is delayed. For example, bleeding



**Figure 51.3.** Acute hemarthrosis and its sequelae in a patient with hemophilia B. Note the periarthral swelling in the left leg and the marked atrophy of the thigh muscles as a result of recurrent hemarthrosis. (Courtesy of Dr. John Lukens.)

after a tooth extraction may stop completely, only to recur in a matter of hours and to persist despite the use of styptics, vasoconstrictors, and packing. The temporary hemostatic adequacy of the platelet plug despite defective blood coagulation may explain this phenomenon of delayed bleeding, as well as the fact that patients with coagulation disorders seldom bleed abnormally from small superficial cuts such as razor nicks. In contrast, posttraumatic or postoperative surgical bleeding in thrombocytopenic patients usually is immediate in onset, as a rule responds to local measures, and rarely is as rapid or voluminous as that encountered in patients with coagulation disorders. However, it may persist for hours or days after surprisingly small injuries.

Valuable information often is obtained from a careful review of dental procedures, because most patients have had one or more teeth extracted at some time during their lives. Inquiry should clarify whether the extractions were single or multiple, the size and location of the tooth or teeth, any treatment given, and the amount, if any, of direct operative trauma. The amount of bleeding normally encountered varies greatly, but as a rough guide, uncomplicated extraction of a single molar tooth may result in brisk bleeding for up to 1 hour and slight oozing for up to 2 days in normal persons (2). Typically, bleeding is more profuse from upper than from lower sockets and is more extensive after extraction of molar teeth, particularly impacted third molars, than after removal of other teeth. In patients with inherited coagulation disorders, the shedding of deciduous teeth often is uncomplicated.

The response to trauma is an excellent screening test for the presence of an inherited hemorrhagic disorder, and a history of surgical procedures or significant injury without abnormal bleeding is equally good evidence against the presence of such a disorder. The removal of molar teeth is a major challenge to hemostasis, as is a tonsillectomy, and it is a rare hemophilic, however mildly affected, who can withstand these procedures without excessive bleeding.

### Miscellaneous Bleeding Manifestations

Despite the fact that structural causes for bleeding (such as polyps, varices, and tumors) are commonly seen in patients with hematuria, hematemesis, and melena, bleeding from these sites may also be associated with both purpuric and coagulation disorders. Severe menorrhagia may be the sole symptom of women with von Willebrand/Willebrand disease (vWD), mild thrombocytopenia, or autosomally inherited coagulation disorders. Recurrent gastrointestinal bleeding or epistaxis in the absence of other bleeding manifestations is common in hereditary hemorrhagic telangiectasia. A coagulation disorder or a disorder of platelet function should be considered if protracted hematuria is the only symptom.

Bleeding into serous cavities and internal fascial spaces often occurs in patients with inherited coagulation disorders and may create serious diagnostic problems. In hemophilia, retroperitoneal hemorrhage or bleeding into the psoas sheath may mimic appendicitis, and hemorrhage into the bowel wall may be confused with intestinal obstruction. Signs and symptoms simulating a variety of acute intraabdominal disorders also may be seen in association with allergic purpura. Bleeding into the central nervous system may complicate thrombocytopenia and may occur after minor trauma in patients with coagulation disorders. Multiple small retinal hemorrhages are common in patients with thrombocytopenia and other purpuric disorders but are uncommon in those with inherited coagulation disorders; large hematomas of the orbit may be seen in the latter group. The coexistence of bleeding and thromboembolic phe-

nomena or bleeding from previously intact venipuncture sites is suggestive of diffuse intravascular coagulation (DIC). Protracted wound healing, wound dehiscence, and abnormal scar formation have been described in inherited afibrinogenemia, the dysfibrinogenemias, and in factor XIII deficiency (3). Hemoptysis rarely is associated with hemorrhagic disorders.

## CLINICAL FEATURES OF INHERITED BLEEDING DISORDERS

An inherited bleeding disorder is suggested by the onset of bleeding symptoms in infancy and childhood, a positive family history (particularly if it reveals a consistent genetic pattern), and laboratory evidence of a single or isolated abnormality, most commonly the deficiency or aberrance of a single coagulation factor.

### Age at Onset: Bleeding in the Neonate

Birth and the neonatal period provide unique challenges to the hemostatic mechanism (4), and bleeding during the first month of life often is the first evidence of an inherited disorder of hemostasis. Small cephalohematomas and petechiae are common in the newborn as a result of the trauma of delivery. Large cephalohematomas that progressively increase in size may result from hemophilia but are more common in association with acquired bleeding disorders such as hemorrhagic disease of the newborn (see Chapter 60). Bleeding from the umbilical stump and after circumcision is common in the acquired coagulation disorders, and it also occurs in the inherited coagulation disorders (5) with the exception of hypofibrinogenemia, dysfibrinogenemia, and factor XIII deficiency. The onset of bleeding from the umbilical cord may be delayed in these latter disorders. In the evaluation of bleeding in the neonate, the clinician should remember that hematochezia and hematemesis may originate from swallowed blood of maternal origin. Simple tests to distinguish such maternal blood from fetal blood have been described (5).

Many infants with inherited coagulation disorders do not bleed significantly in the neonatal period. Less than one-third of patients with hemophilia A and B and only 10% of those with other inherited coagulation disorders have hemorrhagic symptoms during the first week of life. In such patients, the disorder may become clinically silent for a time. Hematomas may first be seen only when the child becomes active. Hemarthrosis commonly does not develop until a child is 3 or 4 years of age.

A mild inherited hemorrhagic disorder may be difficult to distinguish from the insidious onset of an acquired defect. Patients with mild inherited coagulation disorders may enter adult life before characteristic bleeding manifestations occur. These patients and those with some forms of inherited thrombocytopenia and disordered platelet function often describe a history of posttraumatic bruising and hematoma formation that they have come to accept as normal. In hereditary hemorrhagic telangiectasia, the lesions become more prominent with advancing age and may not be symptomatic until middle age. Similarly, in patients with Ehlers-Danlos syndrome, bleeding may not be a problem until adult life.

### Family History

The family history is of great importance in the evaluation of bleeding disorders. In disorders inherited as autosomal-dominant traits with characteristic symptoms and high penetrance, such as hereditary hemorrhagic telangiectasia, an accurate ped-



agree spanning several generations can often be obtained. The presence of typical bleeding manifestations in male siblings and maternal uncles is virtually diagnostic of X-linked recessive inheritance, which characterizes hemophilia A and hemophilia B. In such X-linked traits, the family history also may be helpful in a negative sense—that is, it may clearly exclude the disorder in certain offspring, such as the sons of a known hemophiliac. Details of the various genetic patterns that may be encountered are discussed in the chapters that deal with these conditions.

The limitations of the family history, however, are greater than is commonly realized. Hearsay history is difficult to evaluate, and it is often impossible to assess the significance of easy bruising or to differentiate between manifestations of a generalized bleeding disorder and more common localized lesions, such as peptic ulcer and uterine leiomyomas. In affected families, a bewildering variety of unrelated symptoms is often attributed to bleeding. A negative family history is of no value in excluding an inherited coagulation disorder in an individual patient. As many as 30 to 40% of patients with hemophilia A have a negative family history (6). The family history usually is negative in the autosomal-recessive traits, and consanguinity, which is commonly present in these kindreds, is notoriously difficult to document or exclude.

## CLINICAL FEATURES OF ACQUIRED BLEEDING DISORDERS

Generalized bleeding may be a prominent feature of a wide variety of acquired disorders that encompass virtually the entire field of medicine. Bleeding manifestations usually are less severe than in the inherited forms, and the clinical picture often is dominated by evidence of the underlying disorder rather than by bleeding alone. In the neonate, for example, DIC usually is associated with significant complications such as sepsis, hypoxia, acidosis, or problems related to prematurity. The physician should suspect sepsis or occult thrombosis in any sick neonate with unexplained thrombocytopenia (5). Multiple hemostatic defects commonly are present in patients with acquired hemorrhagic diseases, which often include thrombocytopenia and significant coagulation abnormalities. In contrast, a single abnormality usually is found in patients with inherited hemorrhagic disorders.

In general, the emphasis of the study of the acquired bleeding disorders should be on the patient, not on the laboratory. A thorough history and the physical examination often reveal the cause of thrombocytopenia, such as a drug or acute leukemia. In most vascular disorders, including senile purpura, allergic purpura, scurvy, and amyloidosis, the history and physical examination are of primary diagnostic importance, and the laboratory has little to offer.

## Drug History

The importance of exhaustive interrogation regarding drug use and chemical exposure cannot be overemphasized. The list of drugs associated with thrombocytopenia (see Table 53.5) or vascular purpura grows longer each year. Less common but more serious is drug-induced aplastic anemia, which may present initially with bleeding (see Chapter 44). Many commonly used drugs (see Table 58.4), notably aspirin, impair platelet function and produce abnormal findings on laboratory tests that often lead to expensive and unnecessary additional laboratory studies. The same drugs may provoke bleeding when administered to patients with preexisting hemostatic defects such as hemophilia A.

Drug ingestion also may produce coagulation abnormalities, and drugs that potentiate or antagonize the anticoagulant effects of coumarin derivatives may lead to bleeding or erratic laboratory control. The surreptitious ingestion of such agents is not uncommon.

Results of various coagulation tests may be abnormal in a surprisingly large percentage of hospitalized patients because of heparin that is administered therapeutically or is used in small amounts to maintain the patency of indwelling venous catheters, venous pressure lines, arteriovenous shunts, and various pumps and infusion machines. The partial thromboplastin time (PTT), in particular, may be greatly prolonged in patients who have received even a minute amount of this anticoagulant. Such coagulation abnormalities often are confused with DIC, inhibitors of factor VIII, and other serious coagulation disorders, and they commonly lead to repeated, often detailed, and usually useless coagulation studies. A thorough bedside inventory often is required to find out that heparin is indeed responsible. Prolongation of the thrombin time associated with a normal reptilase time or direct assay of heparin provides laboratory evidence of heparin contamination.

## LABORATORY METHODS FOR STUDY OF HEMOSTASIS AND BLOOD COAGULATION

No single test is suitable for the laboratory evaluation of the overall process of hemostasis and blood coagulation, but methods of varying complexity and use are available for assessing various components and functions individually. The emphasis of the following discussion is on methods that are simple and widely available in most laboratories. The interpretation of the most commonly used tests and the range of values obtained in normal subjects with representative techniques are summarized in Table 51.2. Definitive methods usually require a specially equipped laboratory and trained personnel, and are discussed here from a general standpoint only. Additional comments concerning the use and limitations of the various methods are included in chapters dealing with individual disorders. For details concerning such definitive methods, the reader is referred to more comprehensive works devoted entirely to this subject (7).

## Tests of Vascular and Platelet Phases

### BLEEDING TIME

Hemostasis in a small superficial wound, such as that produced when measuring the bleeding time, depends on the rate at which a stable platelet plug is formed and, thus, provides a measure of the efficiency of the vascular and platelet phases. However, it does not discriminate between vascular defects, thrombocytopenia, and platelet dysfunction. The bleeding time leaves much to be desired in terms of reproducibility because no two skin areas are exactly the same and it is impossible to produce a truly standard wound (8).

Older studies using the bleeding time test supported the view that this test might be helpful in predicting bleeding in individual patients (9). More recent studies suggest that a bleeding time result is determined not only by platelet number and function, but also by hematocrit (10), certain components of the coagulation mechanism (11,12), skin quality (13), and technique (14). A careful analysis of this literature indicates that there is no correlation between a skin template bleeding time and certain visceral bleeding times (14,15), and that no correlation exists between preoperative bleeding time results and surgical blood loss or transfusion requirements (16).



TABLE 51.2. Interpretation of Common Tests of Hemostasis and Blood Coagulation

Test	Normal Range <sup>a</sup> (±SD) and Reference	Common Causes of Abnormalities
Platelet count		
Phase microscopy	140,000–440,000/ $\mu$ l	Thrombocytopenia, thrombocytosis
Automated	177,000–406,000/ $\mu$ l	
Partial thromboplastin time (activated) <sup>b</sup>	26–37 sec; (51) <sup>c</sup>	Deficiencies or inhibitors of prekallikrein; high-molecular-weight kininogen; factors XII, XI, IX, VIII, X, and V; prothrombin or fibrinogen; lupus inhibitors; heparin
Prothrombin time <sup>b</sup>	12.0–15.5 sec; (62) <sup>c</sup>	Deficiencies or inhibitors of factors VII, X, and V; prothrombin or fibrinogen; dysfibrinogenemia; lupus inhibitors; heparin
Thrombin time <sup>b</sup>	18–22 sec; (7)	Afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and hyperfibrinogenemia; inhibitors of thrombin (heparin) or fibrin polymerization (fibrin degradation products, paraproteins)
Fibrinogen assay <sup>b</sup>	150–430 mg/dl; (68)	Afibrinogenemia, dysfibrinogenemia, and hypofibrinogenemia; inhibitors of thrombin or fibrin polymerization
Factor VIII assay <sup>b</sup>	50–150 U/dl; (7)	Hemophilia A and von Willebrand disease; acquired antibodies to factor VIII
Fibrin degradation product assay	0–5 $\mu$ g/ml; (77)	Disseminated intravascular coagulation; fibrinogenolysis; thrombolytic drugs, liver disease; dysfibrinogenemia

<sup>a</sup>Normal range in the University of Utah coagulation laboratory.<sup>b</sup>Tests affected by heparin.<sup>c</sup>Significant variations depending on reagents and technique.

A clinical outcomes study reported that discontinuation of the bleeding time in a major academic medical center had no detectable adverse clinical impact (17). A position paper of the College of American Pathologists and the American Society of Clinical Pathologists concluded that the bleeding time was not effective as a screening test, and that a normal bleeding time does not exclude a bleeding disorder (18). Patients thought to have a platelet-type bleeding disorder based on their personal or family history (or both) should be evaluated for vWD and the inherited qualitative platelet disorders using assays discussed in the section Platelet Function Assays. Newer assays that may be useful in screening patients for platelet dysfunction are also discussed in the section New Assays of Platelet Function.

### PLATELET ENUMERATION

Platelets are considerably more difficult to count than erythrocytes or leukocytes. This difficulty is to be expected in view of the small size of these cells and their tendency to adhere to foreign surfaces and to aggregate when activated.

In general, techniques for platelet counting may be classified into three groups: hemacytometer or direct methods, in which whole blood is diluted and the platelets are counted in much the same way as leukocytes or erythrocytes; semiautomated methods, in which the number of platelets in plasma prepared by sedimentation or centrifugation is determined in an electronic particle counter; and fully automated electronic methods. Virtually identical values for the normal range of the platelet count have been obtained with modern methods, as summarized in Table 51.2.

An estimate of platelet numbers in a well-prepared blood smear by an experienced observer is a valuable check on the platelet count as determined by any method. In general, when a blood smear is examined at 100 $\times$  power, each platelet seen/field represents approximately 10,000 platelets  $\times 10^9$ /L. Consequently, a normal blood smear should demonstrate, on average, at least 14 platelets/high-power field.

Instruments for totally automated platelet counting are widely used. Details of automated cell counters are discussed in Chapter 1. When automated methods are used, various nontechnical factors may produce falsely low platelet counts (19). These factors include platelet agglutinins (20), abnormal amounts of plasma proteins in various paraproteinemias, previous contact of platelets with foreign surfaces such as dialysis membranes (21),

giant platelets, platelet satellitism (22), lipemia (23), and ethylenediaminetetraacetic acid-induced platelet clumping (24), a phenomenon that may produce platelet clumps of sufficient size to artifactually increase the leukocyte count (25). Spuriously high platelet counts may result from the presence of microspherocytes (26), fragments of leukemic cells (27), and Pappenheimer bodies (28). Special technical modifications and the use of careful manual counting methods may be required to eliminate these artifacts and to obtain accurate platelet counts.

### PLATELET VOLUME MEASUREMENTS

The widespread availability of particle counters in the clinical laboratory now permits the accurate measurement of platelet volume on a routine basis. Mean platelet volume (MPV) is increased in disorders associated with accelerated platelet turnover as the result of large numbers of megathrombocytes (29) or in patients with Bernard-Soulier syndrome. Normal or decreased values for MPV usually are obtained in patients with disorders associated with deficient platelet production, in some patients with sepsis (30), and in people with certain big-spleen syndromes (31).

Some authors suggest that increased MPV provides evidence of accelerated platelet production and may be interpreted in the same way as the reticulocyte count. The method is difficult to standardize, however, and when determined on routinely collected specimens by automated counters, it is affected by numerous variables pertaining to specimen collection, anticoagulant, temperature, and duration of storage (32). In view of these problems and the difficulty in interpreting platelet size heterogeneity under normal and abnormal conditions (33), these measurements should be interpreted with caution. Nevertheless, this method is potentially valuable, and estimates of MPV are obtained with currently available instruments at essentially no additional cost.

The presence of microcytic platelets in patients with some inherited thrombocytopenias such as Wiskott-Aldrich syndrome is reliably reflected by MPV measurements. On the other hand, giant platelets associated with Bernard-Soulier syndrome may be counted as leukocytes or erythrocytes and may not be reflected in the MPV.

### PLATELET FUNCTION ASSAYS

Since the 1960s, platelet aggregation using platelet-rich plasma has been the standard method to assess platelet function. This